ライフサイエンスコーパス: mortality risk

1 1.96; p = 0.02) each independently conferred mortality risk.

2 mall but statistically significant increased mortality risk.

3 exposures were all associated with increased mortality risk.

4 hylloquinone with incident CVD and all-cause mortality risk.

5 elp identify coinfected patients with higher mortality risk.

6 n linked to cardiovascular disease (CVD) and mortality risk.

7 tized for interventions and policy to reduce mortality risk.

8 erm follow-up is needed to better assess the mortality risk.

9 CVI) is associated with increased stroke and mortality risk.

10 e to the optimal dose) further increased the mortality risk.

11 ow changes in these factors alter individual mortality risk.

12 ture, altered gut microbiota and have a high mortality risk.

13 ack generalizable, cross-scale indicators of mortality risk.

14 e matrix through which animals disperse with mortality risk.

15 sugar intake is associated with an increased mortality risk.

16 g hemoglobinopathy patients did not increase mortality risk.

17 ansitions across multimorbidity patterns and mortality risk.

18 ial distribution of greenspace in cities and mortality risk.

19 ent air pollution and cardiovascular disease mortality risk.

20 ext] exposure contributes to cardiopulmonary mortality risk.

21 ted with blood culture positivity and 28-day mortality risk.

22 Cox regression was used to assess mortality risk.

23 ays (1.8; 1.1-2.9) increased post-transplant mortality risk.

24 ompeting risks regression to assess waitlist mortality risk.

25 take, intake of different sugar sources, and mortality risk.

26 r meat intake were associated with increased mortality risk.

27 on between urban greenspace distribution and mortality risk.

28 igher SRH was strongly associated with lower mortality risk.

29 han BMI, should be considered in relation to mortality risk.

30 Septic shock carries a high mortality risk.

31 ithin the first week independently increased mortality risk.

32 are associated with increased morbidity and mortality risk.

33 mprove our ability to monitor and anticipate mortality risk.

34 ral atherosclerosis, and with cardiovascular mortality risk.

35 s is associated with reductions in all-cause mortality risk.

36 Repeated HFHs further increased mortality risk.

37 grip strength (GS) is associated with lower mortality risk.

38 rail recipients may be a marker of increased mortality risk.

39 rmed HLA DSA is associated with an increased mortality risk.

40 actors such as pathogen burden and extrinsic mortality risk.

41 City cohort, elderly patients are at highest mortality risk.

42 ore age 40 years, yields large reductions in mortality risk.

43 nically ventilated patients face the highest mortality risk.

44 th pure AR, AR + MR + TR exhibit the largest mortality risk.

45 may contribute to a higher epigenetic-based mortality risk.

46 , but there was no significant difference in mortality risk.

47 ss attenuation of CAV progression and higher mortality risk.

48 sociated with disease progression and higher mortality risk.

49 a modest but persistent increased long-term mortality risk.

50 hydrate reserves and an unrealistically high mortality risk.

51 s increased over time, as has its associated mortality risk.

52 It may also be related to an increased mortality risk.

53 itting increasing cardiovascular disease and mortality risk.

54 2.07-6.62, p < 0.0001), but did not increase mortality risk.

55 nd IT does not confer additional in-hospital mortality risk.

56 surveillance studies estimating RSV-related mortality risk.

57 urgery significantly increases morbidity and mortality risks.

58 should consider the urban-rural disparity in mortality risks.

59 for whom anaemia can increase morbidity and mortality risks.

60 g an emergency operation realize the average mortality risk?

61 ars of delivery in both England and Canada-a mortality risk 11-12 times higher than for control mothe

62 Each day of delay increased mortality risk 5 to 6%.

63 lume surgeons and hospitals had the greatest mortality risk (5.0%), except in the case of older-sick

64 mortality (2635 vs 6881 90-day deaths; crude mortality risk, 5.49% vs 1.22%; adjusted absolute risk d

65 haracteristics, absolute reductions in total mortality risk (6.4 percentage points, 95% CI 0.1-12.7)

66 This group had a 4.54 times higher all-cause mortality risk (95% CI 4.07-5.06) than that of children

67 ness and an ATE of 25.6% reduction in 30-day mortality risk (95% CI, 18.9-32.3; P < .0001) estimated

68 confidence intervals (CI) of overall cancer mortality risk, according to quartiles (q) of the index.

69 y trees will die, than survive, and describe mortality risk across all levels of water stress.

70 We aimed to compare all-cause mortality risk across clusters of adults >=50 years of a

71 who accepted DCD50 offers had 49% decreased mortality risk (adjusted hazard ratio [aHR] (0.46) 0.51(

72 This translated to a 2.22-fold higher mortality risk (adjusted hazard ratio [aHR]: (2.15) 2.22

73 m/s, patients with Vmax >/=5 m/s had greater mortality risk (adjusted hazard ratio=1.86 [1.55-2.54];

74 t benzodiazepine prescription also increased mortality risk after consideration of duration of OAT (a

75 The gradual alteration of mortality risk after ICU admission was assessed using le

76 dysfunction was a potent predictor of 1-year mortality risk after incident HFHs.

77 Mortality risk after kidney transplantation can vary sig

78 (6.4 percentage points, 95% CI 0.1-12.7) and mortality risk after transition (5.7 percentage points,

79 Analyses were adjusted for underlying mortality risk (age, Injury Severity Score, serious brai

80 R, 0.80; 95% CI, 0.65-0.97) but had a higher mortality risk (aHR, 2.00; 95% CI, 1.59-2.55) afterward;

81 hereas MELD 35-40 candidates had a 68% lower mortality risk (aHR: 0.110.320.90, P = 0.03).

82 ]: 2.493.494.89, P < 0.001), but a 62% lower mortality risk (aHR: 0.310.380.46, P < 0.001) beyond thi

83 s who accepted an SDL had a 7.88-fold higher mortality risk (aHR: 4.807.8812.93, P < 0.001) in the fi

84 hereas MELD 35-40 candidates had a 68% lower mortality risk (aHR:0.110.320.90, p=0.03).

85 aHR]:2.493.494.89, p<0.001), but a 62% lower mortality risk (aHR:0.310.380.46, p<0.001) beyond this.

86 s who accepted an SDL had a 7.88-fold higher mortality risk (aHR:4.807.8812.93, p<0.001) in the first

87 in widespread areas (i.e. it projected a low mortality risk), although the model highlighted critical

88 Assuming a base-case 1.64% mortality risk among children 1-59 months old, 3.1% amon

89 the United States have reported an increased mortality risk among individuals with NAFLD, but the pop

90 the United States have reported an increased mortality risk among individuals with NAFLD; therefore,

91 Sitting is associated with all-cause and CVD mortality risk among the least physically active adults;

92 ular yogurt consumption was related to lower mortality risk among women.

93 idea using the specific factor of extrinsic mortality risk, an important factor in evolutionary theo

94 A prognostic score that reflects the mortality risk and an outcome of death or survival was t

95 gs suggest short sedentary bouts still carry mortality risk and are not a healthful alternative to pr

96 pecies-driven by an interaction between nest mortality risk and brood size-and predicted the age of f

97 iduals within populations vary enormously in mortality risk and longevity, but the causes of this var

98 This study demonstrated extremely high mortality risk and medical cost increases for severe CKD

99 was associated with incremental increases in mortality risk and medical costs and reductions in life

100 This study sought to assess mortality risk and morbidity patterns in patients with i

101 ess, coinfected patients still have a higher mortality risk and more severe hepatocellular carcinoma

102 Mortality risks and costs for moderate CKD, heart diseas

103 ine and Gray method to account for competing mortality risk, and Andersen-Gill modeling to analyze to

104 interval (CI): 2.82, 3.05) higher all-cause mortality risk, and participants who increased their CPD

105 sis of hazard ratios (HRs) was performed for mortality risk, and pooled odds ratios (PORs) were calcu

106 Mortality risk appears increased with obesity in infants

107 rventions for men and older women at highest mortality risk are needed to improve HIV treatment outco

108 dels to stratify patients according to their mortality risk are needed.

109 association between chili pepper intake and mortality risk are scarce, with a lack of studies from M

110 Liver carcinoma and mortality risks are increased in individuals with clinic

111 was independently associated with 30% higher mortality risk (aRR, 1.30, 95% CI: 1.26 - 1.34).

112 Mortality risk as a function of event duration was estim

113 ers: (1) diagnosis, (2) patient morbidity or mortality risk assessment, (3) disease outbreak predicti

114 determined the frequency, risk factors, and mortality risk associated with DFU-ISIs.

115 model was fitted to ascertain the all-cause mortality risk associated with each cluster.

116 nsorship and used Cox regression to estimate mortality risk associated with IRD kidney acceptance ver

117 Significantly elevated respiratory disease mortality risk associated with long-term O(3) exposure w

118 The mortality risk associated with PH among patients with ad

119 The mortality risk associated with PH among patients with ad

120 rials, identified an absolute 4.6% increased mortality risk associated with PTXD use.

121 However, the change in mortality risk associated with such a transition remains

122 The excess mortality risk associated with TAPSE <17 mm was noticed

123 ealth, there are few studies quantifying the mortality risk associated with their co-occurrence in th

124 years, incident HFH was associated with high mortality risk at 1 year, declining but remaining elevat

125 ere stratified and analyzed by categories of mortality risk at ICU admission.Measurements and Main Re

126 shaped association with BMI, with the lowest mortality risks at 22.5 kg/m(2) for both men and women.

127 To quantify and compare 9-year all-cause mortality risk attributable to modifiable risk factors a

128 splantation (HTx) recipients experience high mortality risk attributed to increased nonadherence to i

129 ed to NHW patients, NHB patients had a lower mortality risk before 24 months (aHR, 0.80; 95% CI, 0.65

130 Further studies are warranted to assess the mortality risk beyond the first month after RSV illness

131 This may increase mortality risk but may also increase treatment duration,

132 sease, sTNFR1 predicted short-to-medium term mortality risk but not risk of progressive renal functio

133 s >20E% were associated with a 30% increased mortality risk, but increased risks were also found at i

134 ensive care treatment have a high short-term mortality risk, but this alters favorably with increasin

135 population, one should consider the variable mortality risks by ethnicity.

136 the role of matrix on movement behaviour and mortality risk, can incorporate species distribution to

137 llected data from the Swedish Apolipoprotein Mortality Risk cohort on persons 35 to 79 years old who

138 M) has been associated with a higher 10-year mortality risk compared to patients with single primary

139 s who were 30-day survivors of first stroke, mortality risk compared with the general population rema

140 migrants had comparable or lower injury and mortality risks compared to respondents remaining in Ban

141 a 38% (95% CI, 6% to 80%) increased relative mortality risk, corresponding to 4.6% absolute increase,

142 We found that the mortality risk decreased with time after the RSV episode

143 as not associated with a change in operative mortality (risk difference, -0.69%; 95% CI, -2.7% to 1.3

144 The main outcome was the mortality risk difference at the study-specific follow-u

145 The 10-year mortality risk difference for HCV infection was 4.3% (95

146 lem that implicates inequities and extrinsic mortality risk - documenting more future-oriented thinki

147 te HIV- and tuberculosis-associated COVID-19 mortality risks due to residual confounding, both HIV an

148 low high gradient SAS displayed considerable mortality risk during follow up compared with normal flo

149 Mortality risk escalated continuously with increasing nu

150 ally associated with increased morbidity and mortality risks, especially in elderly patients.

151 tilation was associated with lower all-cause mortality risk, even among persistent clean fuel users (

152 ed to elevated cardiometabolic and all-cause mortality risk, extending our understanding about the ro

153 Age was an independent mortality risk factor (P <= .04).

154 the interaction effect between all potential mortality risk factors and the treatment group.

155 EV characteristics by race in the context of mortality risk factors have not been described.

156 nic risk scores (PRS) for 13 diseases and 12 mortality risk factors into sex-specific composite PRS (

157 y attenuated after adjusting for non-genetic mortality risk factors measured at study entry (i.e., mi

158 ct was similar in magnitude to that of known mortality risk factors.

159 iffer by race and sex and is associated with mortality risk factors.

160 gnificantly associated with several clinical mortality risk factors: high-sensitivity C-reactive prot

161 nt knowledge of ARDS trends in incidence and mortality, risk factors, and recently described endotype

162 os (SMRs) to compare cause-specific relative mortality risk following cHL to that expected in the gen

163 r analyses have attempted to quantify excess mortality risk for astronauts exposed to space radiation

164 Observed mortality risk for patients randomized to placebo, 62% o

165 There was a beneficial association with mortality risk for replacing total sedentary time with b

166 fection types (for example, 3.11-fold higher mortality risk for sepsis vs 1.62-fold for a UTI).

167 We evaluated mortality risks for cardiovascular disease, ischemic hea

168 PAD are at lower risk for MACE and all-cause mortality, risk for limb events was similar between sexe

169 Higher nut intake was associated with lower mortality risk from both cardiovascular and noncardiovas

170 lity, quantifies a continuous probability of mortality risk from hydraulic failure.

171 e but not in Hp1 carriers, who had increased mortality risk from intensive therapy.

172 e combined proxy indicators of morbidity and mortality risk from the most recent Demographic and Heal

173 ients continue to face increased nonlymphoma mortality risks from multiple, potentially preventable c

174 Norway using survey data in three cities and mortality risks from the Emerging Risk Factor Collaborat

175 e previously-derived Emergency Heart failure Mortality Risk Grade for 7-day (EHMRG7) and 30-day (EHMR

176 r the discrimination of patients with 90-day mortality risk >=10%.

177 Temperature-related mortality risks have mostly been studied in urban areas,

178 e, was independently associated with greater mortality risk (hazard ratio =1.13 per +1 SD [95% CI, 1.

179 Preferred recipients had no increased mortality risk (hazard ratio [HR]: 0.921.041.16, p=0.5)

180 Preferred recipients had no increased mortality risk (hazard ratio [HR]: 0.921.041.16; P = 0.5

181 entinoids was also associated with increased mortality risk; however, for z-drugs there was no eviden

182 ates was associated with increased wait-list mortality risk (HR 2.6; CI 1.2-5.4).

183 nonpreferred recipients had a 41% increased mortality risk (HR: 1.171.411.70, p<0.001) and 39% incre

184 nonpreferred recipients had a 41% increased mortality risk (HR: 1.171.411.70; P < 0.001) and 39% inc

185 .5 and < 12.5 were associated with increased mortality risk (HR: 3.33, 95% CI 1.23-8.99, p = 0.018 an

186 derstanding the impact of Pb exposure on CVD mortality risk in adults.

187 Mortality risk in children with neurological impairment

188 D3] at diagnosis are associated with a lower mortality risk in colorectal cancer (CRC) patients.

189 The role of extrinsic mortality risk in driving behaviour is probably importan

190 This group had a markedly higher mortality risk in early adulthood than that of other chi

191 stic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never

192 evaluate how use of these treatments altered mortality risk in HIV-positive adults with multidrug-res

193 tant predictor of disease susceptibility and mortality risk in humans and other social mammals.

194 of the strongest predictors of morbidity and mortality risk in humans.

195 n (CrAg) titers are strongly associated with mortality risk in individuals with HIV-associated crypto

196 dialysis vintage is associated with a higher mortality risk in KTR, and this association might be exp

197 Predicting mortality risk in patients is important in research sett

198 lucidate the findings of increased all-cause mortality risk in patients receiving basal insulin, espe

199 BS) is commonly used as a predictor of early mortality risk in patients with bloodstream infections (

200 cancer is associated with a higher all-cause mortality risk in patients with NSCLC, which is partly m

201 tic enrichment strategy to estimate baseline mortality risk in pediatric septic shock.Objectives: To

202 d (b) the shortcomings of MELD in predicting mortality risk in rural areas.

203 thromboembolism is associated with increased mortality risk in some populations, but how frequently i

204 d patients with a 46.4% (95% CI 37.8%-55.2%) mortality risk in the high-risk group compared to 12.5%

205 to power in predicting short and medium-term mortality risk in the overall cohort: AUROCS for liver r

206 The estimated 10-year all-cause mortality risk in the scenario in which no PLwH had HCV

207 ion models were used to assess predictors of mortality risk in these patients.

208 y or myomectomy is associated with increased mortality risk in women with occult uterine cancer.

209 ower morcellation was associated with higher mortality risk in women with occult uterine sarcoma, esp

210 During the study period, firearm mortality risks increased in Mexico and Brazil but decre

211 y of any intensity is needed to mitigate the mortality risks incurred by sedentary time.

212 ept for telomere length were associated with mortality risk independently of CA.

213 16) who underwent a high (>=1%) or low (<1%) mortality risk inpatient surgical procedures.

214 Taking excess mortality risk into consideration, this reduction in the

215 verweight and obese men did not have a lower mortality risk, irrespective of WL.

216 In angiosperms, drought-related mortality risk is associated with lower resistance (low

217 tangling the roles of movement behaviour and mortality risk is fundamental to accurately interpreting

218 The association between urban greenspace and mortality risk is well known, but less is known about ho

219 e had increased all-cause and cardiovascular mortality risks (log rank P=0.004 and P=0.003, respectiv

220 e measured to assign a PERSEVERE-II baseline mortality risk.Measurements and Main Results: Among 379

221 This mortality risk model allows early risk stratification of

222 A multivariable mortality risk model including the SpO(2)/FiO(2) ratio,

223 ally significant associations with increased mortality risk: multivariable-adjusted HR (95% CI) in th

224 eyed physicians for their estimates of 7-day mortality risk, obtained for each patient before knowled

225 We clarify that the mortality risk of a short birth interval to an offspring

226 nown about the all-cause and cancer-specific mortality risks of dual- and poly-tobacco use.

227 ed with expected population survival, excess mortality risks of pure AR, AR + OMR, and AR + FMR were

228 , p = 0.049) to be independent predictors of mortality risk on admission in severe COVID-19 patients.

229 We observed a higher mortality risk over 5 years in the pericarditis group, e

230 ity groupings improved the stratification of mortality risk, particularly when applied 6 h after PARD

231 The associated mortality risk per 1 higher comorbidity also increased s

232 Annual mortality risk per thousand tons of precursor emissions

233 ld, 3.1% among children 1-5 months old, 4.4% mortality risk post-discharge, and 13.5% mortality reduc

234 Herein, we aim to assess mortality risk prediction in peritoneal dialysis patient

235 Six-year lung cancer incidence and mortality risk predictions were assessed for (1) calibra

236 sting that hypochloremia may account for the mortality risk previously attributed to hyponatremia.

237 t TMAO quartile had a crude 1.86-fold higher mortality risk (Ptrend < 0.001).

238 ths (HR 1.7; CI 1.0-2.8) increased wait-list mortality risk; pulmonary exacerbation time 15-28 days (

239 s associated with physiologic impairment and mortality risk.PurposeTo determine whether participant-l

240 with increased all-cause and cause-specific mortality risk, ranging from 39% to 126%.

241 (mosquitoes observed, n = 7380): cumulative mortality (risk ratio 0.99, 95% confidence interval [CI]

242 tion was not associated with a difference in mortality (risk ratio, 0.90; 95% CI, 0.74-1.10; p = 0.31

243 se who reported fair to poor health (10-year mortality risk ratio, 1.06 [CI, 0.82 to 1.37]).

244 ood health at baseline (for example, 10-year mortality risk ratio, 1.62 [CI, 1.37 to 1.90]) but not a

245 are to be associated with CVD and all-cause mortality risk reduction.

246 erranean diet reduced cardiovascular disease mortality risk related to long-term exposure to air poll

247 Mortality risks relative to the population in diagnosed

248 For unknown reasons, mortality risk remains high even after hospital discharg

249 Predicting longer-term mortality risk requires collection of clinical data, whi

250 hen transitioning to a culture with a higher mortality risk (rGNB and Candida spp).

251 hen transitioning to a culture with a higher mortality risk (rGNB and Candida spp.).

252 e or absence of CA, provided robust hospital mortality risk stratification.

253 The Swedish Apolipoprotein-Related Mortality Risk study is a longitudinal cohort study incl

254 and cessation of solid fuel use cuts excess mortality risks swiftly and substantially within 5 years

255 Mortality risk tended to be increased for all major caus

256 trast, Hispanic patients had a lower overall mortality risk than NHW patients (aHR, 0.61; 95% CI, 0.5

257 , obese women with WL < 5% had a lower 60-mo mortality risk than normal-weight women with WL < 5% (ad

258 ese women with WL >= 5% did not have a lower mortality risk than normal-weight women with WL < 5%.

259 Women with higher education had lower mortality risks than less-educated women, except first-d

260 uppression (IS) is associated with decreased mortality risk that is not fully explained by attenuatio

261 water relations, as a potential indicator of mortality risk that is physiologically relevant and inte

262 additionally used other tobacco products had mortality risks that were as high and sometimes higher t

263 Compared with the observed 15.4% mortality risk, the estimated 10-year risks of mortality

264 reduces agility and increases predation and mortality risk to subordinates.

265 virus (HIV) increases cardiovascular disease mortality risks to a greater degree among women than men

266 time required for adjusted rehospitalization/mortality risks to decline 50% from maximum values after

267 vered vital status data, the excess relative mortality risk was 27% (95% CI, 3%-58%).

268 Pooled early mortality risk was 3.30% (95% CI, 2.39-4.55), late morta

269 In infancy, mortality risk was amplified by obesity, whereas in olde

270 Mortality risk was calculated 56 days from enrolment.

271 46% of mortality risk was explained by multivariable modelling

272 Excess mortality risk was found for concordant causes of death

273 The lowest mortality risk was found with added sugar intakes betwee

274 When compared with controls, the overall mortality risk was greatest in the first year after diag

275 k group with a four-fold increase in suicide mortality risk was identified based on the out-of-sample

276 The mortality risk was likewise present for patients diagnos

277 g status, and inotrope requirement, waitlist mortality risk was lower at Adult Congenital Heart Assoc

278 Measles mortality risk was lower for children living in a campai

279 on DRP, and for gabapentinoids the increased mortality risk was not specific to DRP.

280 Significantly lower mortality risk was observed when saturated fatty acids,

281 The relative increase in mortality risk was present in all age groups and was gre

282 This reduction in hospital mortality risk was seen across the 4 different U.S. cens

283 e adjacent position on the kidney match-run, mortality risk was significantly higher for next-sequent

284 Mortality risk was similar in participants with >0.5-1.0

285 Increased mortality risks were associated with low and high temper

286 The predicted prestage 1 and 2 mortality risks were calculated for each patient.

287 ving further from childbirth facilities, but mortality risks were not lower despite this increased se

288 Physicians should consider competing mortality risks when recommending anticoagulants to olde

289 is often related to severity of illness and mortality risk, whereas overtreatment or undertreatment

290 V remodeling conferred a >2-fold increase in mortality risk, which remained significant (p < 0.01) wh

291 benefit was defined as absolute reduction in mortality risk with KT.

292 .44 additional points to equalize children's mortality risk with the age-standardized mortality rate

293 rately rank children and equalize children's mortality risk with the age-standardized mortality rate

294 Survival curves suggest that increased mortality risk with two 148M alleles was greatest beginn

295 weak evidence for elevated CVD and all-cause mortality risks with more sitting among those meeting th

296 was associated with a reduction in all-cause mortality risk within 1 year (hazard ratio, 0.73 [95% CI

297 rovide a web-based application that computes mortality risk within 120 days.

298 d in men than in women, but did not increase mortality risk within our cohort.

299 Lifetime breast cancer mortality risk without screening was 10% to 11% across m

300 een religious service attendance and reduced mortality risk, yet research identifying mediators remai